Table of Content

1. Research Methodology


2. Chimeric Antigen Receptor (CAR) T Cell Therapy - Next Era in Immuno Oncology


3. Evolution of Chimeric Antigen Receptor (CAR) T-Cell Design
3.1 Structure of CAR-T Cell
3.2 1st Generation Chimeric Antigen Receptor
3.3 2nd & 3nd Generation CAR-T Cell
3.4 Principle of Chimeric Antigen Receptor Design


4. Approaches to Improve the Efficacy of CAR-T Cell Therapy


5. CAR T Cell Therapy Manufacturing Cost Analysis


6. Emerging In-Vivo Induced CAR T Cell Therapies
6.1 Need of In-Vivo CAR T Cell Therapy
6.2 In-Vivo CAR T Cell Platform; VivoVec, TumorTag, & RACR/CAR
6.3 Key Drug in Research & Development


7. Global CAR T Cell Therapy Market Oulook 2022 - 2028
7.1 Market Overview
7.2 Future Market Opportunity


8. Globally Approved CAR T Cell Therapies – Pricing, Dosage & Sales Analysis 2028
8.1 Tisagenlecleucel (Kymriah)
8.2 Axicabtagene Ciloleuce (Yescarta)
8.3 Brexucabtagene Autoleucel (Tecartus)
8.4 Lisocabtagene maraleucel (Breyanzi)
8.5 Idecabtagene Vicleucel (Abecma)
8.6 Relmacabtagene autoleucel (Carteyva)
8.7 Ciltacabtagene autoleucel (Carvykti)


9. US CAR T Cell Therapy Market Outlook
9.1 Approved & Key CAR T Cell Therapy Products in US
9.2 Market Overview
9.3 Current Reimbursement Scenario


10. Europe CAR T Cell Therapy Market Outlook
10.1 Approved & Key CAR T Cell Therapy Products in Europe
10.2 UK
10.3 Germany
10.4 Spain
10.5 France
10.6 Rest of Europe
10.7 Current Reimbursement Scenario


11. China CAR T Cell Therapy Market Outlook
11.1 Approved & Key CAR T Cell Therapy Products in China
11.2 Current Market Size & Forecast


12. Japan CAR T Cell Therapy Market Outlook
12.1 Approved & Key CAR T Cell Therapy Products in Japan
12.2 Market Overview
12.3 Current Reimbursement Scenario


13. South Korea CAR T Cell Therapy Market Outlook
13.1 Approved & Key CAR T Cell Therapies in South Korea
13.2 Future Market Opportunity

14. Australia CAR T Cell Therapy Market Outlook
14.1 Approved & Key CAR T Cell Products in Australia
14.2 Australia CAR T Cell Therapy Market
14.3 Current Reimbursement Scenario


15. Taiwan CAR T Cell Therapy Market Outlook


16. Global CAR T Cells Clinical Pipeline Overview
16.1 By Company
16.2 By County
16.3 By Indication
16.4 By Phase


17. Global CAR T Cells Clinical Pipeline By Company, Indication & Phase
17.1 Research
17.2 Preclinical
17.3 Clinical
17.4 Phase-I
17.5 Phase-I/II
17.6 Phase-II
17.7 Phase-III
17.8 Registered


18. Marketed CAR T Cell Therapy Clinical insight
18.1 Breyanzi
18.2 CARVYKTI
18.3 Yescarta
18.4 Kymriah
18.5 Abecma
18.6 Tecartus


19. Global CAR-T Cell Therapy Market Dynamics
19.1 Favorable Parameters
19.2 Market Challenges


20. Competitive Landscape
20.1 Autolus
20.2 Bellicum
20.3 Bluebird
20.4 Celgene
20.5 Cellectis
20.6 Celyad
20.7 Eureka Therapeutics
20.8 Fortress Biotech
20.9 Immune Therapeutics
20.10 Juno Therapeutics
20.11 Kite Pharma
20.12 Novartis
20.13 Sorrento therapeutics
20.14 TILT Biotherapeutics
20.15 Ziopharm
 



List of Tables

Table 3-1: Antigens which are targeted by Chimeric Antigen Receptor
Table 5-1: CAR T Cell – Per Production Cost (US$)
Table 6-1: Advantage of VivoVec Platform over Traditional Platform
Table 6-2: ENLIGHTen – Phase I Trial Initiation & Completion Year
Table 9-1: US – FDA Approved CAR T Cell Therapy Products
Table 10-1: Europe – Approved CAR T Cell Therapy Products
Table 12-1: Japan – MHLW Approved CAR T Cell Therapy Products
Table 14-1: Australia –Approved CAR T Cell Therapy Products
Table 20-1: Clinical Pipelines of Products